
|Videos|February 23, 2022
- Vol 67 No 3
- Volume 67
- Issue 3
Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
Author(s)Lindsey Carr, Editor
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Advertisement
If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.
Articles in this issue
over 4 years ago
Delayed diagnosis of a bowel injury at laparoscopyover 4 years ago
Understanding abnormal uterine bleeding in adolescentsover 4 years ago
Adnexal torsion requires careful diagnosis, managementover 4 years ago
Bringing awareness to endometriosisover 4 years ago
Celebrating Laura E. Riley, MDalmost 5 years ago
Prenatal genetic data sharing and privacy risksalmost 5 years ago
Patient perspectives on vulvovaginal candidiasisalmost 5 years ago
Provider bias in contraceptive counselingAdvertisement
Related to this article

Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.

A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.

A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.

The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.

As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.

Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.

Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
March of Dimes: United States earns fifth straight D+ for preterm birth
2
US loses measles elimination status; ACOG releases statement
3
Kristin MacGregor, PhD, on identifying perinatal depression
4
Testosterone for women: Global consensus and physiologic dosing
5

